Shares of Alamar Biosciences, Inc. climbed Tuesday after the precision proteomics company reported second-quarter revenue growth of 82% and issued full-year revenue guidance for the first time as a public company, building on strong momentum since its initial public offering earlier this year.

The stock closed up 17.58% at $32.91, on volume of 168,730 shares, well below its three-month average of about 285,808 shares, giving the company a market capitalization of approximately $2.28 billion.

Alamar Biosciences, based in Fremont, California, reported total revenue of $29.4 million for the second quarter of 2026, an increase of 82% compared with the same period a year earlier, according to results released after market close Monday. The results followed a strong first quarter, when the company reported revenue of $26 million, up 99% year-over-year, extending a pattern of rapid growth since the company's commercial launch of its precision proteomics platform.

Yuling Luo, the company's co-founder, chairman and chief executive, described the quarter as a continuation of the company's recent momentum. "Q2 2026 was a strong quarter that reflects the momentum of our business," Luo said on the company's earnings call, adding that total revenue grew 82% year-over-year and that consumable revenue, which the........

© International Business Times